Radiopharmaceutical companies Nuclidium and Actithera have raised significant funds to advance their drug pipelines. Nuclidium completed a $99 million Series B round to support clinical development of copper isotope-based diagnostic and therapeutic agents, aiming to overcome production and supply challenges. Actithera closed a $75 million Series A financing to initiate clinical trials of fibroblast activation protein (FAP)-targeted radiopharmaceuticals with enhanced tumor retention. Both companies are capitalizing on increased investor interest in targeted radiation therapies exemplified by recent market successes. These financing rounds demonstrate growing confidence in radiopharma as a therapeutic modality with potential applications across cancer types.